A Prospective, Randomized Clinical Trial to Prevent Intra-abdominal Infection After Pancreatic Surgery Using Serum Lactate Levels

What this Trial Is About

Postoperative intra-abdominal infection is a serious complication following pancreatic surgery, which can lead to significant suffering, longer hospital stays, and potentially life-threatening conditions like sepsis. Researchers are studying whether preventive use of antibiotics during surgery, guided by serum lactate level changes on the first day after surgery, can reduce the rate of these infections. This study aims to confirm previous findings that a peak serum lactate level above 3.25 mmol/L within 24 hours after surgery predicts infection risk. Participants with a peak serum lactate level over 3.25 mmol/L on postoperative day one will be randomly assigned to one of two groups. One group receives advanced antibiotics (Sulperazon 3g every 8 hours) for five days after surgery, while the other group receives routine antibiotics (Cefmetazole 1g every 12 hours) for three days. This randomized controlled trial compares infection rates and other outcomes between these two preventive antibiotic strategies. During the study, researchers will monitor participants for 30 days after surgery, assessing the incidence of intra-abdominal infection as the primary outcome. Additional blood tests will track white blood cell counts, procalcitonin, C-reactive protein, interleukin, and tumor necrosis factor alpha levels at multiple points up to 28 days post-surgery. The study also evaluates complications, hospital costs, and overall recovery to determine if advanced antibiotics improve patient outcomes after pancreatic resection.

Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes